Multi-omics and imaging mass cytometry characterization of human kidneys to identify pathways and phenotypes associated with impaired kidney function.

Deceased kidney donors arachidonic acid imaging mass cytometry kidney damage kidney inflammation lipidomics metabolic pathways

Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
29 Feb 2024
Historique:
received: 18 11 2022
revised: 16 01 2024
accepted: 24 01 2024
medline: 3 3 2024
pubmed: 3 3 2024
entrez: 2 3 2024
Statut: aheadofprint

Résumé

Despite the recent advances in our understanding of the role of lipids, metabolites and related enzymes in mediating kidney injury, there is limited integrated multi-omics data identifying potential metabolic pathways driving impaired kidney function. The limited availability of kidney biopsies from living donors with acute kidney injury has remained a major constraint. Here, we validated the use of deceased transplant donor kidneys as a good model to study acute kidney injury in humans and characterized these kidneys using imaging and multi-omics approaches. We noted consistent changes in kidney injury and inflammatory markers in donors with reduced kidney function. Neighborhood and correlation analyses of imaging mass cytometry data showed that subsets of kidney cells (proximal tubular cells and fibroblasts) are associated with the expression profile of kidney immune cells, potentially linking these cells to kidney inflammation. Integrated transcriptomic and metabolomic analysis of human kidneys showed that kidney arachidonic acid metabolism and seven other metabolic pathways were upregulated following diminished kidney function. To validate the arachidonic acid pathway in impaired kidney function we demonstrated increased levels of cytosolic phospholipase A2 protein and related lipid mediators (prostaglandin E2) in the injured kidneys. Further, inhibition of cytosolic phospholipase A2 reduced injury and inflammation in human kidney proximal tubular epithelial cells in vitro. Thus, our study identified cell types and metabolic pathways that may be critical for controlling inflammation associated with impaired kidney function in humans.

Identifiants

pubmed: 38431215
pii: S0085-2538(24)00168-6
doi: 10.1016/j.kint.2024.01.041
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Evans O Asowata (EO)

Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK and Gothenburg, Sweden; Department of Surgery, University of Cambridge and NIH Cambridge Biomedical Research Centre, Cambridge, UK.

Simone Romoli (S)

Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK and Gothenburg, Sweden.

Rebecca Sargeant (R)

Imaging and Data Analytics, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK.

Jennifer Y Tan (JY)

Imaging and Data Analytics, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK.

Scott Hoffmann (S)

Imaging and Data Analytics, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK.

Margaret M Huang (MM)

Department of Surgery, University of Cambridge and NIH Cambridge Biomedical Research Centre, Cambridge, UK.

Krishnaa T Mahbubani (KT)

Department of Surgery, University of Cambridge and NIH Cambridge Biomedical Research Centre, Cambridge, UK.

Fynn N Krause (FN)

Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK and Gothenburg, Sweden; Department of Biochemistry, University of Cambridge, Cambridge, UK.

Daniel Jachimowicz (D)

Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.

Rasmus Agren (R)

Translational Science and Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Albert Koulman (A)

NIHR BRC Core Metabolomics and Lipidomics Laboratory, University of Cambridge, Cambridge, UK.

Benjamin Jenkins (B)

NIHR BRC Core Metabolomics and Lipidomics Laboratory, University of Cambridge, Cambridge, UK.

Barbara Musial (B)

Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK and Gothenburg, Sweden.

Julian L Griffin (JL)

Department of Biochemistry, University of Cambridge, Cambridge, UK.

Magnus Soderberg (M)

Department of Pathology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.

Stephanie Ling (S)

Imaging and Data Analytics, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK.

Pernille B L Hansen (PBL)

Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK and Gothenburg, Sweden.

Kourosh Saeb-Parsy (K)

Department of Surgery, University of Cambridge and NIH Cambridge Biomedical Research Centre, Cambridge, UK.

Kevin J Woollard (KJ)

Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK and Gothenburg, Sweden.

Classifications MeSH